Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 26, 2026Sponsor estimate | NCT07861542Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Sanofi · COVID-19 | SNYLead | Phase 4 | Active, not recruiting | Locked | Locked | Locked |
| Nov 27, 2026Sponsor estimate | NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · Hypercholesterolaemia | NVSLead | Phase 4 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy Volunteers | BMYLead | Phase 4 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 26, 2026Sponsor estimatePhase 4NCT07861542Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Sanofi · COVID-19Active, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2026Sponsor estimatePhase 4NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · HypercholesterolaemiaRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 4NCT04314375Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17...Bausch Health Americas, Inc. · Ulcerative ColitisRecruitingBHCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 4NCT07564310INFORMing Patients With Oximetry Data to Improve MAD EngagementResMed · Obstructive Sleep Apnea (OSA)Not yet recruitingRMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2026Sponsor estimatePhase 4NCT07884175A Study of Updated mRNA Seasonal Influenza VaccinesModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 4NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 4NCT06372925Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial InfarctionNovartis Pharmaceuticals · Plaque, AtheroscleroticActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 13, 2027Sponsor estimate | NCT06897527A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)GlaxoSmithKline · Neoplasms, Endometrial | GSKLead | Phase 4 | Not yet recruiting | Locked | Locked | Locked |
| Jan 23, 2027Sponsor estimate | NCT06332014Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland ChinaAmgen · Osteoporosis | AMGNLead | Phase 4 | Active, not recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT07813026Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational...Viatris Inc. · Healthy | VTRSLead | Phase 4 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 13, 2027Sponsor estimatePhase 4NCT06897527A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)GlaxoSmithKline · Neoplasms, EndometrialNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2027Sponsor estimatePhase 4NCT06332014Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland ChinaAmgen · OsteoporosisActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 4NCT07813026Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational...Viatris Inc. · HealthyRecruitingVTRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 3, 2027Sponsor estimate | NCT06422689Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareAstraZeneca · Asthma | AZNLead | Phase 4 | Active, not recruiting | Locked | Locked | Locked |
| Feb 7, 2027Sponsor estimate | NCT07905547A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisSanofi · Atopic Dermatitis | SNYLeadREGNCollaborator | Phase 4 | Not yet recruiting | Locked | Locked | Locked |
- Primary completion Feb 3, 2027Sponsor estimatePhase 4NCT06422689Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareAstraZeneca · AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 7, 2027Sponsor estimatePhase 4NCT07905547A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic DermatitisSanofi · Atopic DermatitisNot yet recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.